Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aslan Pharmaceuticals Ltd ADR
(NQ:
ASLN
)
0.4437
+0.0086 (+1.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aslan Pharmaceuticals Ltd ADR
< Previous
1
2
3
4
5
Next >
ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting
May 15, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
April 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting
April 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Presents New Data From Atopic Dermatitis Candidate
September 28, 2022
Via
Benzinga
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
March 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
10 Short Squeeze Candidates: PaxMedica, Blue Apron, MicroStrategy And More
March 20, 2023
Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits...
Via
Benzinga
ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
March 14, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
March 10, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata
March 08, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata
February 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
February 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 24, 2023
Via
Benzinga
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 24, 2023
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 24, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
February 24, 2023
It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!
Via
InvestorPlace
ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
February 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
February 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 12, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 04, 2023
Via
Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 04, 2023
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...
Via
Benzinga
ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies
January 03, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
December 16, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients
December 15, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference
November 21, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference
November 08, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 28, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 19, 2022
Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.